Serum from patients with ankylosing spondylitis can increase PPARD, fra-1, MMP7, OPG and RANKL expression in MG63 cells

Authors

  • Zaiying Hu Sun Yat-Sen University; Department of Rheumatology
  • Dongfang Lin Sun Yat-Sen University; Department of Rheumatology
  • Jun Qi Sun Yat-Sen University; Department of Rheumatology
  • Minli Qiu Sun Yat-Sen University; Department of Rheumatology
  • Qing Lv Sun Yat-Sen University; Department of Rheumatology
  • Qiuxia Li Sun Yat-Sen University; Department of Rheumatology
  • Zhiming Lin Sun Yat-Sen University; Department of Rheumatology
  • Zetao Liao Sun Yat-Sen University; Department of Rheumatology
  • Yunfeng Pan Sun Yat-Sen University; Department of Rheumatology
  • Ou Jin Sun Yat-Sen University; Department of Rheumatology
  • Yuqiong Wu Sun Yat-Sen University; Department of Rheumatology
  • Jieruo Gu Sun Yat-Sen University; Department of Rheumatology

DOI:

https://doi.org/10.6061/clinics/2015(11)04

Abstract

OBJECTIVES: To explore the effects of serum from patients with ankylosing spondylitis on the canonical Wnt/β-catenin pathway and to assess whether the serum has an osteogenic effect in MG63 cells. METHODS: MG63 cells were cultured with serum from 45 ankylosing spondylitis patients, 30 healthy controls, or 45 rheumatoid arthritis patients. The relative PPARD, fra-1, MMP7, OPG and RANKL mRNA levels were measured using quantitative real-time polymerase chain reaction. Associations between gene expression and patient demographics and clinical assessments were then analyzed. RESULTS: MG63 cells treated with serum from ankylosing spondylitis patients had higher PPARD, fra-1, MMP7 and OPG gene expression than did cells treated with serum from controls or rheumatoid arthritis patients (all p<0.05). RANKL expression was higher in MG63 cells treated with serum from patients with ankylosing spondylitis or rheumatoid arthritis than in those treated with serum from controls (both p<0.05). The OPG/RANKL ratio was also higher in MG63 cells treated with serum from ankylosing spondylitis patients than in those treated with serum from controls (p<0.05). No associations were found between the expression of the five genes and the patient demographics and clinical assessments (all p>;0.05). CONCLUSIONS : Serum from ankylosing spondylitis patients increases PPARD, fra-1, MMP7, OPG and RANKL expression and the OPG/RANKL ratio in MG63 cells; these effects may be due to the stimulatory effect of the serum on the Wnt pathway.

Downloads

Download data is not yet available.

Downloads

Published

2015-11-01

How to Cite

Hu, Z., Lin, D., Qi, J., Qiu, M., Lv, Q., Li, Q., Lin, Z., Liao, Z., Pan, Y., Jin, O., Wu, Y., & Gu, J. (2015). Serum from patients with ankylosing spondylitis can increase PPARD, fra-1, MMP7, OPG and RANKL expression in MG63 cells . Clinics, 70(11), 738-742. https://doi.org/10.6061/clinics/2015(11)04

Issue

Section

Clinical Sciences